- Revance Therapeutics (NASDAQ:RVNC) -33% after FDA declines to approve wrinkle injection.
- MannKind (NASDAQ:MNKD) -18% as FDA declines to approve United Therapeutics’ heart disease drug
- Omeros (NASDAQ:OMER) -17% after FDA fails to approve narsoplimab treatment.
- Aditxt (NASDAQ:ADTX) -16% on pricing $4.25 million public offering.
- Avadel Pharmaceuticals (NASDAQ:AVDL) -14% after FDA says it needs more time to review narcolepsy candidate.
- TSR (NASDAQ:TSRI) -10%.
- Nxt-ID (NASDAQ:NXTD) -10%.
- LM Funding America (NASDAQ:LMFA) -9%.
- UP Fintech Holding (NASDAQ:TIGR) -9%.
- BiomX (NYSE:PHGE) -7% after mid-stage results from BX001 skin acne study.
- Futu Holdings (NASDAQ:FUTU) -7%.
- Zillow Group (NASDAQ:ZG) -7% to pause home purchases after building up backlog - Bloomberg.
- Cemtrex (NASDAQ:CETX) -6%.
- Latch (NASDAQ:LTCH) -6%.
- Jasper Therapeutics (NASDAQ:JSPR) -6%.
- DatChat (NASDAQ:DATS) -6%.
- Ocugen (NASDAQ:OCGN) -6% announces inducement grants
- Standard Lithium (NYSE:SLI) -5%.